| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EBIOM.2018.01.016 |
| P8608 | Fatcat ID | release_wmqeo6m2sfhqzfeywsuqfvuepu |
| P932 | PMC publication ID | 5835568 |
| P698 | PubMed publication ID | 29396294 |
| P2093 | author name string | Diane Goltz | |
| Friedrich Bootz | |||
| Dimo Dietrich | |||
| Heidrun Gevensleben | |||
| Jennifer Landsberg | |||
| Jörn Dietrich | |||
| Lea Kristin Röver | |||
| P2860 | cites work | Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy | Q42027896 |
| Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. | Q46675575 | ||
| Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | Q48594003 | ||
| PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas | Q50054711 | ||
| CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. | Q52096226 | ||
| Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. | Q55463248 | ||
| Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. | Q55463985 | ||
| Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma | Q56895636 | ||
| PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia | Q88754466 | ||
| Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 | ||
| Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma | Q24612429 | ||
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| The PD-1 pathway in tolerance and autoimmunity | Q24633549 | ||
| Immune Evasion Strategies of Glioblastoma | Q26765855 | ||
| CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition | Q26777563 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas | Q27853175 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Targeting immune checkpoints in malignant glioma | Q28072012 | ||
| RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome | Q29547458 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype | Q29617457 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| PD-L1 regulates the development, maintenance, and function of induced regulatory T cells | Q30080038 | ||
| The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis. | Q33835174 | ||
| PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy | Q34544461 | ||
| Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies | Q34592058 | ||
| Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. | Q35244289 | ||
| Comprehensive analyses of tumor immunity: implications for cancer immunotherapy | Q37193493 | ||
| Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas | Q37435455 | ||
| Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours | Q38148501 | ||
| Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma | Q38393470 | ||
| Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma | Q38453759 | ||
| Tumor infiltrating immune cells in gliomas and meningiomas. | Q38555703 | ||
| Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy | Q38794624 | ||
| The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 | ||
| CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients | Q39334962 | ||
| Bioinformatic profiling identifies an immune-related risk signature for glioblastoma | Q39736294 | ||
| PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients | Q40208391 | ||
| P304 | page(s) | 97-104 | |
| P577 | publication date | 2018-01-31 | |
| P1433 | published in | EBioMedicine | Q24912341 |
| P1476 | title | PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations | |
| P478 | volume | 28 |
| Q58766030 | Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas |
| Q56891027 | CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients |
| Q89576428 | Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma |
| Q58552781 | Epigenetic regulators of programmed death-ligand 1 expression in human cancers |
| Q91934018 | IDH mutation in glioma: molecular mechanisms and potential therapeutic targets |
| Q52682578 | Methylation of PD-1 Promoter Gene as New Prognostic Marker for IDH Mutant Low-Grade Glioma? |
| Q99622572 | Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma |
| Q93042164 | PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters |
| Q61813473 | PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression |
| Q97525213 | PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis |
| Q89737172 | Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy |
| Q98224804 | Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression |
| Q61449923 | The Prognostic and Therapeutic Value of PD-L1 in Glioma |
Search more.